Related Experiment Video

Updated: Dec 28, 2025

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.3K

Tigecycline therapy in pediatric patients with multidrug resistant bacteremia

Aslinur Ozkaya-Parlakay1, Belgin Gulhan1, Saliha Kanik-Yuksek1

  • 1Ankara Hematology Oncology Children's Training and Research Hospital, Pediatric Infectious Disease Department, Ankara, Turkey.

Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)
|February 22, 2020
PubMed

Insights

Tigecycline shows promise for treating severe pediatric infections caused by multidrug-resistant (MDR) bacteria, with high rates of microbiological eradication and clinical response. Further research is warranted for this important therapeutic option in children.

Area of Science:

  • Pediatric Infectious Diseases
  • Antimicrobial Resistance
  • Pharmacology

Background:

  • Multidrug resistance (MDR) in bacteria necessitates novel therapeutic strategies.
  • Tigecycline offers a broad spectrum of activity against MDR pathogens.
  • Tigecycline is not yet approved for pediatric use.

Purpose of the Study:

  • To retrospectively assess the effectiveness and safety of tigecycline in pediatric patients.
  • To evaluate tigecycline as a treatment option for severe infections in children.

Main Methods:

  • Retrospective analysis of 36 pediatric patients treated with tigecycline.
  • Tigecycline administered as combination therapy for a median of 13 days.
  • Evaluation of microbiological eradication and clinical response rates.

Main Results:

  • Microbiological eradication achieved in 75% of patients (27/36).
  • Clinical response observed in 83% of patients (30/36).
  • Relapse occurred in 17% of cases (6/36).

Conclusions:

  • Tigecycline demonstrates potential as a treatment option for pediatric severe infections.
  • Effective against infections caused by multidrug-resistant bacteria in children.
  • Supports further investigation into tigecycline for pediatric populations.
Abstract

Keywords:
BacteremiaBacteriemiaChildrenMultidrug-resistantMultirresistenteNiñosTigeciclinaTigecycline

More Related Videos

Author Spotlight: Photodynamic Therapy as a Novel Approach to Induce Petite Colonies in Drug-Resistant Candida for Antifungal Research09:06

Author Spotlight: Photodynamic Therapy as a Novel Approach to Induce Petite Colonies in Drug-Resistant Candida for Antifungal Research

Published on: March 29, 2024

1.0K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R2029106:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.1K

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
485
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
159
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
172
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
229
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
146
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
202